Activation of mTOR is involved in anti-β2GPI/β2GPI-induced expression of tissue factor and IL-8 in monocytes

Thrombosis Research

Volumn 157, Issue , 2017, Pages 103-110

  Xia, Longfei ^b,c   Zhou, Hong ^a,b   Wang, Ting ^b   Xie, Yachao ^b   Wang, Xiaoyan ^b   Yan, Jinchuan ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Anti 2 glycoprotein I antibodies; Interleukin 8; mTOR; Tissue factor; 2 glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPID ANTIBODY; RAPAMYCIN; RESATORVID; STRESS ACTIVATED PROTEIN KINASE; THROMBOPLASTIN; TOLL LIKE RECEPTOR 4; IL8 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL ACTIVATION; CELL VIABILITY ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; THROMBOSIS; WESTERN BLOTTING; GENETICS; METABOLISM;

HUMANS; INTERLEUKIN-8; MONOCYTES; THROMBOPLASTIN; TOR SERINE-THREONINE KINASES;

EID: 85024384842     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.05.023     Document Type: Article

References (33)

1. Ruiz-Irastorza, G., Crowther, M., Branch, W., Khamashta, M.A., Antiphospholipid syndrome. Lancet 376:9751 (2010), 1498–1509.
2. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4:2 (2006), 295–306.
3. Tanne, D., Katzav, A., Beilin, O., Grigoriadis, N.C., Blank, M., Pick, C.G., et al. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol. Dis. 30:1 (2008), 56–64.
4. Alard, J.E., Gaillard, F., Daridon, C., Shoenfeld, Y., Jamin, C., Youinou, P., TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J. Immunol. 185:3 (2010), 1550–1557.
5. Sciascia, S., Sanna, G., Khamashta, M.A., Cuadrado, M.J., Erkan, D., Andreoli, L., et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann. Rheum. Dis. 74:11 (2015), 2028–2033.
6. Zhou, H., Sheng, L., Wang, H., Xie, H., Mu, Y., Wang, T., et al. Anti-β2GPI/β2GPI stimulates activation of THP-1 cells through TLR4/MD-2/MyD88 and NF-κB signaling pathways. Thromb. Res. 132:6 (2013), 742–749.
7. Hamid, C., Norgate, K., D'Cruz, D.P., Khamashta, M.A., Arno, M., Pearson, J.D., et al. Anti-β2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann. Rheum. Dis. 66:8 (2007), 1000–1007.
8. Xia, L., Zhou, H., Hu, L., Xie, H., Wang, T., Xu, Y., et al. Both NF-kappaB and c-Jun/AP-1 involved in anti-β2GPI/β2GPI-induced tissue factor expression in monocytes. Thromb. Haemost. 109:4 (2013), 643–651.
9. Sorice, M., Longo, A., Capozzi, A., Garofalo, T., Misasi, R., Alessandri, C., et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 56:8 (2007), 2687–2697.
10. Thomson, A.W., Turnquist, H.R., Raimondi, G., Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9:5 (2009), 324–337.
11. Laplante, M., Sabatini, D.M., mTOR signaling in growth control and disease. Cell 149:2 (2012), 274–293.
12. Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99:16 (1999), 2164–2170.
13. Sousa, J.E., Costa, M.A., Abizaid, A.C., Rensing, B.J., Abizaid, A.S., Tanajura, L.F., et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104:17 (2001), 2007–2011.
14. Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seihean, D., Noël, L.H., et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371:4 (2014), 303–312.
15. Sousa, J.E., Costa, M.A., Abizaid, A., Abizaid, A.S., Feres, F., Pinto, I.M., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103:2 (2001), 192–195.
16. Zhou, H., Wolberg, A.S., Roubey, R.A., Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 104:8 (2004), 2353–2358.
17. Xie, H., Zhou, H., Wang, H., Chen, D., Xia, L., Wang, T., et al. Anti-beta(2)GPI/beta(2)GPI induced TF and TNF-alpha expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol. Immunol. 53:3 (2013), 246–254.
18. Agar, C., van Os, G.M., Mörgelin, M., Sprenger, R.R., Marquart, J.A., Urbanus, R.T., et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 116:8 (2010), 1336–1343.
19. Zhou, H., Yan, Y., Xu, G., Zhou, B., Wen, H., Guo, D., et al. Toll-like receptor (TLR)-4 mediates anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells. Clin. Exp. Immunol. 163:2 (2011), 189–198.
20. Xu, G., Wen, H., Zhou, H., Guo, D., Zhou, F., Chen, D., et al. Involvement of IRAKs and TRAFs in anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells. Thromb. Haemost. 106:6 (2011), 1158–1169.
21. Xia, L., Xie, H., Yu, Y., Zhou, H., Wang, T., Yan, J., The effects of NF-κB and c-Jun/AP-1 on the expression of prothrombotic and proinflammatory molecules induced by anti-β2GPI in mouse. PLoS One, 11(2), 2016, e0147958.
22. Xie, H., Sheng, L., Zhou, H., Yan, J., The role of TLR4 in pathophysiology of antiphospholipid syndrome-associated thrombosis and pregnancy morbidity. Br. J. Haematol. 164:2 (2014), 165–176.
23. Zhou, H., Chen, D., Xie, H., Xia, L., Wang, T., Yuan, W., et al. Activation of MAPKs in the anti-β2GPI/β2GPI-induced tissue factor expression through TLR4/IRAKs pathway in THP-1 cells. Thromb. Res. 130:4 (2012), e229–e235.
24. Canaud, G., Legendre, C., Terzi, F., AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. Lupus 24:3 (2015), 227–230.
25. Lin, H.Y., Chang, K.T., Hung, C.C., Kuo, C.H., Hwang, S.J., Chen, H.C., et al. Effects of the mTOR inhibitor rapamycin on monocyte-secreted chemokines. BMC Immunol., 15, 2014, 37.
26. Baker, A.K., Wang, R., Mackman, N., Luyendyk, J.P., Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression inmacrophages by reducing IL-10 expression. Mol. Immunol. 46:11 − 12 (2009 Jul), 2249–2255.
27. Bozic, B., Cucnik, S., Kveder, T., Rozman, B., Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmun. Rev. 4:5 (2005), 303–308.
28. Vega-Ostertag, M., Casper, K., Swerlick, R., Ferrara, D., Harris, E.N., Pierangeli, S.S., Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 52:5 (2005), 1545–1554.
29. Sun, R., Zhang, Y., Ma, S., Qi, H., Wang, M., Duan, J., et al. Down-regulation of mitogen-activated protein kinases and nuclear factor-κB signaling is involved in rapamycin suppression of TLR2-induced inflammatory response in monocytic THP-1 cells. Microbiol. Immunol. 59:10 (2015), 614–622.
30. Edwards, M.W., Aultman, J.A., Harber, G., Bhatt, J.M., Sztul, E., Xu, Q., et al. Role of mTOR downstream effector signaling molecules in Francisella tularensis internalization by murine macrophages. PLoS One, 8(12), 2013, e83226.
31. Kawamoto, T., Ii, M., Kitazaki, T., Iizawa, Y., Kimura, H., TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur. J. Pharmacol. 584:1 (2008), 40–48.
32. Yu, M., Kang, X., Xue, H., Yin, H., Toll-like receptor 4 is up-regulated by mTOR activation during THP-1 macrophage foam cells formation. Acta Biochim. Biophys. Sin. Shanghai 43:12 (2011), 940–947.
33. Duarte, J.H., Connective tissue diseases: mTORC is a potential therapeutic target in APS. Nat. Rev. Rheumatol., 10(9), 2014, 513.